Approved for GvHD, Deployed for Antiaging
One Drug, Two Indications
The capital is pricing amimestrocel as a longevity asset. The NMPA's January 2025 conditional approval was for acute graft-versus-host disease, a life-threatening immune reaction that can follow bone marrow transplant. Conditional approval (China's National Medical Products Administration's pathway for drugs showing early efficacy in a serious unmet need before full trial completion) is not indication-general, meaning any patient or consumer using it for antiaging purposes has no regulatory finding behind them. By mid-2025, amimestrocel was deployed across more than 70 transplant centers in China.
This month, the Second Medical Center of the PLA General Hospital in Beijing, known as 301 Hospital, opened enrollment for 2,000 adults aged 50 and older in a stem cell antiaging trial using amimestrocel. It is the first large-scale antiaging trial at a state-tier Chinese institution. The drug, trade name Ruibosheng, uses mesenchymal stem cells (adult stem cells with regenerative and immune-modulating properties) derived from umbilical cord tissue. The endpoint is unspecified. Enrollment at 301 Hospital opened in June 2026. The NMPA has not published a primary endpoint for antiaging trials.
Four Agencies, No Framework
74 billion across 49 financing events in Q1 2026, running 56 percent ahead of Q1 2025. 1 billion, Hong Kong's largest healthcare IPO this year. BlackRock anchored at US$50 million.
Australia's Therapeutic Goods Administration cleared NMN (nicotinamide mononucleotide, an NAD+ precursor that supports cellular energy metabolism) as a permissible therapeutic ingredient on January 15, 2026, the first such regulatory classification globally. Longevity Life Sciences holds sole supply rights through its CellVive NMN brand at Chemist Warehouse. The TGA classified an ingredient. It certified no antiaging efficacy. That difference does not appear on the label.
The NMPA, MOH Singapore's Health Sciences Authority (Singapore's therapeutic-products and clinical-trial regulator), TGA Australia, and PMDA Japan (Japan's Pharmaceuticals and Medical Devices Agency) have collectively published no guidance framework for how a conditional-approval drug extends into an antiaging indication, or what primary endpoint such a trial must report. None has defined the endpoint. BlackRock's US$50 million anchor in METiS closed May 13, 2026. As of that date, the NMPA, HSA, TGA, and PMDA had collectively published no primary-endpoint framework for antiaging trials.
The 2,000 participants enrolling at 301 Hospital in June 2026 are entering a trial whose success criteria the NMPA has not defined. The agency's conditional approval, granted January 2025, covered acute graft-versus-host disease; it has not been extended to aging. BlackRock's US$50 million anchor in METiS settled May 13. METiS reports first-half financials in August. The NMPA has published no antiaging endpoint guidance since. The August filing arrives without it.